Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

curasan AG, DE000A2YPGM4

curasan AG, DE000A2YPGM4

21.11.2019 - 08:15:38

curasan stabilizes portfolio business in the third quarter and intensifies partner search

On September 16, 2019, Torben Sorensen succeeded Michael Schlenk, whose contract would have expired on September 30, 2019, and who resigned from office as of the end of September 15, 2019 as CEO of the company.

"Despite extensive efforts in the past years curasan did not manage to reach the break-even point through growth out of its own remarkable strengths", Torben Sorensen draws up as summary. "In order to get there we aim at comprehensive strategic partnerships with well established providers in the field of medical devices. Furthermore, we are evaluating options to acquire promising complementary products - if appropriate also within or by support of further capital measures - or to sell own products which could be marketed in a better way by third parties. Therefore, it is my number one priority to put these measures on the way in order to be able to operate sustainably as soon as possible."

Based on the new strategy, already in July the company had announced the acquisition of JEDER GmbH located in Klosterneuburg/Vienna, Austria, a provider in the field of dental technology, which will be consolidated with effect of December 31, 2019 for the first time.

By the JEDER technology platform curasan plans to generate additional turnover in the coming year via cross selling. "We can draw important conclusions from the development in the last years. In particular, that our products are without any doubt of premium quality, but also, that this fact alone is not going to secure curasan's success", explains Torben Sorensen. "By product bundling with other high quality products from the dental technology field our quality can be established in the market much faster."

Against the backdrop of the currently reconsolidated operative development of the company the Management Board expects to close the 2019 financial year in line with the full-year forecast. You find more information on Curasan AG and its product range under www.curasan.com.

Contact curasan AG: Andrea Weidner Head of Investor Relations & Corporate Communications +49 6027 40 900-51 ir@curasan.comAbout curasan AG: curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan. curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in Wake Forest, near Raleigh, N.C., USA. curasan's innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange.

21.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: curasan AG Lindigstraße 4 63801 Kleinostheim

Germany Phone: 06027/40 900 0 Fax: 06027/40 900 29 E-mail: info@curasan.de Internet: www.curasan.de ISIN: DE000A2YPGM4 WKN: A2YPGM Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 918411   End of News DGAP News Service

918411  21.11.2019 

@ dgap.de